## Christopher H Hawkes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5044537/publications.pdf

Version: 2024-02-01

60 papers

4,502 citations

304368 22 h-index 50 g-index

63 all docs

63
docs citations

63 times ranked

5829 citing authors

#	Article	IF	CITATIONS
1	Parkinson's disease: a dualâ€hit hypothesis. Neuropathology and Applied Neurobiology, 2007, 33, 599-614.	1.8	776
2	Metaâ€analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	2.8	607
3	A timeline for Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 79-84.	1.1	470
4	Identifying prodromal Parkinson's disease: Preâ€Motor disorders in Parkinson's disease. Movement Disorders, 2012, 27, 617-626.	2.2	443
5	Olfaction in neurodegenerative disorder. Movement Disorders, 2003, 18, 364-372.	2.2	265
6	Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathologica, 2010, 119, 703-713.	3.9	258
7	Parkinson's Disease. Annals of the New York Academy of Sciences, 2009, 1170, 615-622.	1.8	233
8	Is Parkinson's disease a primary olfactory disorder?. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 473-480.	0.2	144
9	Smoking is a risk factor for multiple sclerosis: a metanalysis. Multiple Sclerosis Journal, 2007, 13, 610-615.	1.4	121
10	Olfaction in Neurodegenerative Disorder. , 2006, 63, 133-151.		116
11	The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it?. Movement Disorders, 2008, 23, 1799-1807.	2.2	115
12	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	0.9	90
13	Olfactory Evoked Responses and Identification Tests in Neurological Disease. Annals of the New York Academy of Sciences, 1998, 855, 608-615.	1.8	85
14	Twin studies and the heritability of MS: a conclusion. Multiple Sclerosis Journal, 2009, 15, 661-667.	1.4	85
15	Abnormality of taste and smell in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 232-237.	1.1	79
16	Olfactory tests in the diagnosis of essential tremor. Parkinsonism and Related Disorders, 2008, 14, 563-568.	1.1	67
	303-300 <b>.</b>		
17	Editors' welcome and a working definition for a multiple sclerosis cure. Multiple Sclerosis and Related Disorders, 2013, 2, 65-67.	0.9	59

#	Article	IF	CITATIONS
19	Chemosensory dysfunction in neurodegenerative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 164, 325-360.	1.0	58
20	Parkinson's disease and aging: Same or different process?. Movement Disorders, 2008, 23, 47-53.	2.2	43
21	The McDonald Criteria for Multiple Sclerosis: time for clarification. Multiple Sclerosis Journal, 2010, 16, 566-575.	1.4	43
22	The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. Multiple Sclerosis and Related Disorders, 2012, 1, 9-14.	0.9	37
23	Are multiple sclerosis patients risk-takers?. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 895-911.	0.2	33
24	Olfactory testing in parkinsonism. Lancet Neurology, The, 2004, 3, 393-394.	4.9	18
25	Seroprevalence of herpes simplex virus type 2 in multiple sclerosis. Acta Neurologica Scandinavica, 2006, 114, 363-367.	1.0	16
26	Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Multiple Sclerosis and Related Disorders, 2018, 25, 197-199.	0.9	14
27	Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus?. European Neurology, 2010, 63, 29-35.	0.6	12
28	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2021, 53, 103155.	0.9	12
29	Parosmia: treatment, mechanism, and types. BMJ, The, 2020, 371, m4739.	3.0	11
30	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	0.9	11
31	I've stopped examining patients!. Practical Neurology, 2009, 9, 192-194.	0.5	10
32	Implications of Low-Titer MOG Antibodies. Multiple Sclerosis and Related Disorders, 2022, 59, 103746.	0.9	10
33	Risk associated behavior in premorbid multiple sclerosis: A case-control study. Multiple Sclerosis and Related Disorders, 2014, 3, 40-47.	0.9	9
34	Iso-electric focusing of aqueous humour IgG in multiple sclerosis. Journal of Neurology, 1994, 241, 436-438.	1.8	8
35	Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2019, 33, A1-A2.	0.9	8
36	Smell, taste and COVID-19: testing is essential. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 83-91.	0.2	7

#	Article	IF	Citations
37	Smart handles and red flags in neurological diagnosis. British Journal of Hospital Medicine, 2002, 63, 732-742.	0.3	5
38	Multiple sclerosis genetics is dead. Multiple Sclerosis and Related Disorders, 2013, 2, 156-161.	0.9	5
39	Multiple sclerosis in Latter Day Saints (Mormons). Acta Neurologica Scandinavica, 2007, 115, 260-264.	1.0	4
40	Is the incidence of multiple sclerosis really increasing?. Multiple Sclerosis and Related Disorders, 2020, 45, 102527.	0.9	4
41	Why Bother Testing the Sense of Smell?. Practical Neurology, 2005, 5, 224-229.	0.5	3
42	Get rid of your stethoscope!. Practical Neurology, 2010, 10, 344-346.	0.5	3
43	Air pollution and multiple sclerosis risk. Multiple Sclerosis and Related Disorders, 2021, 48, 102797.	0.9	3
44	Twin Study Using Mortality Data: A New Sampling Method. International Journal of Epidemiology, 1995, 24, 758-762.	0.9	2
45	Comment to letter: "ldentical twins with LRRK2 mutation discordant for Parkinson's disease― Movement Disorders, 2013, 28, 561-561.	2.2	2
46	Is multiple sclerosis overdiagnosed?. Multiple Sclerosis and Related Disorders, 2021, 47, 102721.	0.9	2
47	Melatonin and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 103032.	0.9	2
48	The role of inheritance in sporadic Parkinson's disease. Annals of Neurology, 2000, 47, 682-682.	2.8	1
49	Clinical evaluation., 0,, 59-110.		1
50	General disorders of olfaction. , 0, , 111-152.		1
51	Neuropoppycockology. Practical Neurology, 2009, 9, 347-352.	0.5	1
52	MRI and visual-evoked potentials in partners of multiple sclerosis patients. Acta Neurologica Scandinavica, 2012, 125, 424-430.	1.0	1
53	Multiple sclerosis and risk behavior. Multiple Sclerosis and Related Disorders, 2012, 1, 59-60.	0.9	1
54	Neurodegenerative diseases that affect olfaction. , 2009, , 153-214.		0

#	Article	IF	CITATIONS
55	Investigation, treatment, and general management of olfactory disease., 0,, 215-232.		O
56	Neurodegenerative Chemosensory Disorders. , 0, , 293-386.		0
57	Diagnosing and caring for MS in Haiti. Multiple Sclerosis and Related Disorders, 2018, 22, A1-A2.	0.9	O
58	Grassroot efforts towards diversity in MS care and research: Win-win for patients and science. Multiple Sclerosis and Related Disorders, 2019, 35, A1-A2.	0.9	0
59	Dare we mention the C-word?. Multiple Sclerosis and Related Disorders, 2020, 43, 102340.	0.9	O
60	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. Multiple Sclerosis and Related Disorders, 2021, 56, 103426.	0.9	0